摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Amino-2,5-dimethylbenzimidazole

中文名称
——
中文别名
——
英文名称
4-Amino-2,5-dimethylbenzimidazole
英文别名
2,5-dimethyl-1H-benzimidazol-4-amine
4-Amino-2,5-dimethylbenzimidazole化学式
CAS
——
化学式
C9H11N3
mdl
MFCD03788431
分子量
161.2
InChiKey
ZBEFKPQWLHUQQP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    54.7
  • 氢给体数:
    2
  • 氢受体数:
    2

文献信息

  • [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2019243535A1
    公开(公告)日:2019-12-26
    The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.
    本发明涉及式(I)的O-GIcNAc水解酶(OGA)抑制剂。该发明还涉及包含这种化合物的药物组合物,用于制备这种化合物和组合物的方法,以及利用这种化合物和组合物预防和治疗OGA抑制对其有益的疾病的应用,特别是τ蛋白病,如阿尔茨海默病或进行性核上性麻痹症;以及伴有τ病理的神经退行性疾病,特别是由C90RF72突变引起的肌萎缩侧索硬化和颞叶前叶痴呆症。
  • OGA INHIBITOR COMPOUNDS
    申请人:Janssen Pharmaceutica NV
    公开号:US20210277003A1
    公开(公告)日:2021-09-09
    The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
查看更多